The FDA has approved acoltremon 0.003% ophthalmic solution (Tryptyr – Alcon) for treatment of dry eye disease. Acoltremon is the first transient receptor potential melastatin 8 (TRPM8) thermoreceptor agonist to be approved in the US for this indication.
DRY EYE DISEASE — Disruption of tear-film homeostasis (altered composition, reduced production, rapid evaporation) and resulting ocular surface inflammation cause the discomfort and blurred vision of dry eye disease. Many cases are caused by tear evaporation due to meibomian gland dysfunction. Other precipitating factors include...
- A New Heart Failure Indication for Finerenone (Kerendia)
- Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction
- Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic
- In Brief: Embryotoxicity REMS Removal for Endothelin Receptor Antagonists
- Sunvozertinib (Zegfrovy) for NSCLC (online only)
ISSUE
The FDA has approved the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent HF visits in adults with HF with a left ventricular ejection fraction (LVEF) ≥40%. Finerenone was approved in 2021 to reduce the risk of kidney disease progression and cardiovascular events in adults with chronic kidney disease (CKD) associated with type 2 diabetes.1
STANDARD TREATMENT — Patients with a LVEF of 41-49% have HF with mildly reduced or mid-range ejection fraction (HFmrEF); those with a LVEF ≥50% have heart failure with preserved ejection fraction (HFpEF).2
The oral sodium-glucose cotransporter 2 (SGLT2) inhibitors empagliflozin (Jardiance) and dapagliflozin (Farxiga, and generics) are FDA-approved to reduce the risk of cardiovascular death and …